Summary of Yidu Technology Conference Call Company Overview - **Company**: Yidu Technology - **Fiscal Year**: 2025 - **Key Financials**: - Total revenue: 715 million RMB - Net loss: 135 million RMB, a decrease of 38.9% year-on-year [2][3][10] - Operating cash flow outflow: 250 million RMB, a decrease of 23.8% year-on-year [2][4][11] Key Business Segments 1. AI for Medical - Revenue growth: 10.3% year-on-year in the big data platform and solutions segment [2][10] - AI platform deployed in over 30 top-tier hospitals, reducing medical record writing time to 30 seconds and TNM staging assessment time by 70% [5][14][33] - AI diagnostic assistant served 26,000 patients from February to June 2025 [9][12] 2. AI for Life Science - Revenue: 270 million RMB, a decrease of 23.7% year-on-year [18] - Active clients: 132, with 16 out of the top 20 global pharmaceutical companies as clients [8][18] - Completed 411 clinical trials and 275 real-world studies [7][18] 3. AI for Care - Revenue: 122 million RMB, a decrease of 28% year-on-year [22] - Main operator for Shenzhen and Beijing's health insurance programs, with over 6 million and 15 million insured individuals respectively [24][30] Operational Efficiency - Operating expenses (OPEX) decreased by 23% year-on-year, with OPEX as a percentage of revenue down by 10 percentage points [2][11] - Sales expenses as a percentage of revenue decreased from 26% to 20% [11] - R&D expenses as a percentage of revenue decreased from 29% to 26% [11] AI Model Development - Self-developed medical model's hallucination rate decreased by 80%, trained on over 500 billion tokens [8][10] - Performance in medical scenarios rated better than Deepseek R1 [9] Strategic Initiatives - Launched "1+N+X" product matrix for physician dictation, integrating multiple large models to enhance the entire medical process [5][14] - New data platform EVA 5.0 significantly improved data processing efficiency by over 4 times [15] Future Outlook - Expected revenue growth of approximately 20% in AI for Medical for FY 2026 [29][30] - Focus on high-quality revenue growth in AI for Life Science, with a target to exceed industry growth rates [29][30] - Plans for stock buyback due to current low stock prices, with sufficient cash reserves of approximately 3.78 billion RMB [30] Additional Insights - The company has established a strong presence in the healthcare AI sector, with significant partnerships and projects in various hospitals and research institutions [17][18][35] - Continuous investment in AI technology and data management to maintain competitive advantages in the healthcare market [34][35]